Early Cancer Detection in Dogs with a Simple Blood Draw
The cancer researchers, genomics specialists, data scientists, and veterinarians at PetDx™ bring together the expertise required to deliver this breakthrough Liquid Biopsy technology for the benefit of dogs and their families.
We are excited to share our product launch with the world
6 Million New Cancer Cases Per Year in Dogs
Cancer is by far the single most common cause of death in adult dogs. Like humans, dogs have a 1 in 3 lifetime risk of getting cancer, and approximately 6 million dogs are newly diagnosed with cancer each year in the United States. Older dogs, and certain predisposed breeds, are at higher risk of developing cancer. Cancer is typically diagnosed in dogs at an advanced stage, when treatment options are limited, and chances of a cure are low. Each year, cancer cuts short the lives of many dogs who might have enjoyed many healthy years with their families had the disease been detected earlier.
Cancer is a Disease of the Genome
Each cell in a dog's body contains billions of DNA "letters" that make up the dog's genome. Cancer develops as a result of the successive accumulation of genomic alterations (DNA mutations) over time. All cells release DNA fragments into the bloodstream, and DNA released from cancer cells contains unique genomic alterations that can be detected by liquid biopsy technology.
Introducing OncoK9 –
The Liquid Biopsy Test for Dogs™
OncoK9™ enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms empowering veterinarians to provide superior care to canine patients.
Most cancer tests are either invasive (like a tissue biopsy) or require special equipment (like imaging). OncoK9 requires only a simple blood draw. The sample collection can take place during the same visit when the veterinarian prescribes the test.
OncoK9 has demonstrated cancer signal detection across more than 20 cancer types, including 7 of the most common cancers in dogs.
OncoK9 interrogates millions of cell-free DNA fragments in each blood sample, using sophisticated next-generation sequencing technology and bioinformatics algorithms to detect multiple classes of genomic alterations associated with cancer.
By identifying cancer signal in cell-free DNA extracted from a blood sample, OncoK9 may allow for earlier detection of cancer, before the onset of clinical signs.
How the OncoK9 Liquid Biopsy Test Works
A blood sample contains cell-free DNA fragments released from healthy cells and cancer cells (if cancer is present).
A centrifuge is used to separate the blood sample into 3 components: plasma, buffy coat, and hematocrit.
Cell-free DNA is extracted from plasma and an amplified DNA library is prepared for sequencing.
Next-generation sequencing of the DNA library generates detailed data for analysis.
The lab uses proprietary bioinformatics algorithms to identify cancer-associated genomic alterations.
A clinical report is sent to the veterinarian indicating whether or not cancer signal has been detected.
OncoK9 Intended Use
OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. It is recommended as an annual screening test for all dogs starting at 8 years of age and potentially at younger ages for dogs belonging to breeds that are highly predisposed to cancer. It is also recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient’s medical history and clinical presentation. The test is available by prescription only.
As an oncologist, I am excited about the ways in which the OncoK9 liquid biopsy test will benefit dogs, their families, and the veterinarians that manage their care.
Join the Revolution in Early Cancer Detection for Dogs
If you are eager to incorporate breakthrough innovation into your veterinary practice, we would love to partner with you. Be among the first to offer our pioneering multi-cancer early detection test to your canine patients. Provide your name and email address and we will reach out as we expand our rollout.